Catheter-based Cryotherapy System (CTS)
Stabilization of Vulnerable Coronary Plaque to Prevent Myocardial Infarction
Phase 1Active
Key Facts
Indication
Stabilization of Vulnerable Coronary Plaque to Prevent Myocardial Infarction
Phase
Phase 1
Status
Active
Company
About CryoTherapeutics
CryoTherapeutics is an early-stage European innovator targeting the root cause of most heart attacks: vulnerable atherosclerotic plaque. Their implant-free cryotherapy technology cools plaque to -10°C to -20°C, aiming to stabilize it by reducing inflammation and increasing fibrous cap thickness, thereby lowering rupture risk. The company has completed a first-in-human (POLARSTAR) pilot study showing initial safety and feasibility, positioning it in a large, underserved cardiovascular market. Based in Leuven, Belgium, and founded in 2015, it is a private, pre-revenue company advancing a unique medical device platform.
View full company profile